Andere talen Castle Biosciences, Inc.

Aandelen

CSTL

US14843C1053

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
19,31 ^USD	+0,57%		-3,74%	-10,52%

08/04	Castle Biosciences Insider verkocht aandelen ter waarde van $441.853, volgens een recent SEC-filing	MT
04/04	Castle Biosciences, Inc. kondigt aan nieuwe gegevens te zullen delen op het 20e congres van de European Association of Dermato-Oncology	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024	11/04
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations	10/04
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year	10/04
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	08/04
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer	04/04
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	04/04
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Castle Biosciences Announces Updates to its Board of Directors	27/03
Castle Biosciences, Inc. Announces Board Changes	27/03
Castle Biosciences, Inc. - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years	25/03
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year	25/03
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB	22/03
Castle Biosciences - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	20/03
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	19/03
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology	19/03
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older	15/03
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences and MedTech Investor Forum	13/03
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum	12/03
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting	08/03
Castle Biosciences - In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups	08/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Castle Biosciences, Inc.

Aandelen

CSTL

US14843C1053

Andere talen

Filters